PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(01): 40-43
DOI: 10.4103/0971-5851.133719
ORIGINAL ARTICLE

A study to correlate histopathology, biochemical marker and immunohistochemical expression of sex-steroid receptors in prostatic growth

Sukla Naskar
Department Pathology, Calcutta National Medical College, Kolkata, West Bengal, India
,
Soumya Kanti Kundu
Consultant in Nuclear Medicine, R.N. Tagore Institute of Cardiac Sciences, Kolkata, West Bengal, India
,
Nirmal Kumar Bhattacharyya
Department Pathology, Medical College, Kolkata, West Bengal, India
,
Pranab Kumar Bhattacharyya
Department Pathology, School of Tropical Medicine, Kolkata, West Bengal, India
,
Anup Kumar Kundu
Department of Urology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

Prostate gland is a fibromusculoglandular structure situated at the neck of urinary bladder. So, enlargement or growth of prostate due to nodular hyperplasia (NHP) or prostatic intraepithelial neoplasia (PIN) or adenocarcinoma may give rise to bladder outlet obstruction. Malignant growth i.e., PIN or adenocarcinoma cases are associated with increased blood level of prostate-specific antigen (PSA) and increased expression of different sex-steroid receptors because the growth is dependent on the interactions of androgen, progesterone and estrogen. The aim of our study is to correlate the histopathology, PSA levels and expression of different sex-steroid receptors by immunohistochemistry in different prostatic growth lesions. Among the total 50 cases received, inclusive of transurethral resection of prostate (TURP), transrectal ultrasound-guided biopsy and radical prostatectomy, 34 cases were diagnosed as NHP, 4 cases as PIN and 12 cases as adenocarcinoma histopathologically. Serum PSA values above 10 ng/ml were seen in 2 cases of PIN and 11 cases of adenocarcinoma and none of NHP. Estrogen receptor (ER) () expressions were negative in all cases. Progesterone receptor (PR) expressions were strongly positive in 35% cases of both NHP and adenocarcinoma, whereas androgen receptor (AR) expressions were strong among all cases of adenocarcinoma and only in four cases of NHP. By observing these findings it can be suggested that antiandrogen and antiprogesterone therapy simultaneously will do better than antiandrogen alone in treating prostatic growth lesions.

Keywords

Androgen receptor - immunohistochemistry - progesterone receptor - prostatic growth - prostate-specific antigen


Publikationsverlauf

Artikel online veröffentlicht:
19. Juli 2021

© 2014. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jonathan I. Epstein- the lower urinary tract and male genital system, In: Kumar V, Abbas AK, Fausto N, Editors, Robbins and Cotran Pathologic basis of disease, 7 th ed, Chapter 21, Saunders: Elsevier; reprint 2006. p.1047,48,50,55.
  • 2 Yeole BB, Jussawalla DJ. Descriptive epidemiology of the cancers of male genital organs in greater Bombay. Indian J Cancer 1997;34:30-9.
  • 3 Rosai J, Ackerman. Male reproductive system, prostate and seminal vesicles. In: Rosai J, Ackerman, Editors. Rosai and Ackerman′s surgical pathology, 9 th ed, Vol. 1, Chapter 18, New Delhi: Mosby, Elsevier; reprint 2005. p. 1361-62,1369.
  • 4 Chakrabarti S, Raha K, Bhunia CL, Bhattachary DK. Department of Pathology, North Bengal Medical College and Hospital, Siliguri, The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma. J Indian Med Assoc 2001;99:627-8, 630.
  • 5 Androgen receptor, Wikipedia, the free encyclopedia, 22 September, 2010.
  • 6 Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 1999;155:641-7.
  • 7 Progesteron receptor, Wikipedia, the free encyclopedia, 18 September, 2010.
  • 8 Men S, Cakar B, Conkbayir I, Hekimoglu B. Detection of prostatic carcinoma: The role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density. J Exp Clin Cancer Res 2001;20:473-80.
  • 9 Aboseif S, Shinohara K, Weidner N, Narayan P, Carroll PR. The significance of prostatic intra-epithelial neoplasia. Br J Urol 1995;76:355-9.
  • 10 Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
  • 11 Wernert N, Gerdes J, Loy V, Seitz G, Scherr O, Dhom G. Investigations of the estrogen (ER-ICA-test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis. Virchows Arch A Pathol Anat Histopathol 1988:412:387-91.
  • 12 Kang MS, Park SY, Yoon HK. Estrogen and Progesterone Receptor Expressions in Benign Prostatic Hypertrophy and Prostatic Adenocarcinoma. Korean J Pathol 1998;32:346-51.
  • 13 Hiramatsu M, Maehara I, Orikasa S, Sasano H. Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma. Histopathology 1996;28:163-8.
  • 14 Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Progesterone receptor expression in human prostate cancer: Correlation with tumor progression. Prostate 2001;48:285-91.
  • 15 Qiu YQ, Leuschner I, Braun PM. Androgen receptor expression in clinically localized prostate cancer: Immunohistochemistry study and literature review. Asian J Androl 2008;10:855-63.
  • 16 Brolin J, Andersson L, Ekman P. Steroid receptor profile and receptor stability in subfractions of human prostatic tissues, Urol Res 1991;19:327-31.